In AML, an aggressive hematologic malignancy, the overexpression of the SET oncoprotein, able to inhibit the protein phosphatase PP2A, is a key event that correlates with poor prognosis [97]. The gene discussed is PTPA; the disease is acute myeloid leukemia.